Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression

  • Donal McHugh
  • Nicole Caduff
  • Mario Henrique M Barros
  • Patrick C Rämer
  • Ana Raykova
  • Anita Murer
  • Vanessa Landtwing
  • Isaak Quast
  • Christine T Styles
  • Michael Spohn
  • Adeola Fowotade
  • Henri-Jacques Delecluse
  • Alexandra Papoudou-Bai
  • Yong-Moon Lee
  • Jin-Man Kim
  • Jaap Middeldorp
  • Thomas F Schulz
  • Ethel Cesarman
  • Andrea Zbinden
  • Riccarda Capaul
  • Robert E White
  • Martin J Allday
  • Gerald Niedobitek
  • David J Blackbourn
  • Adam Grundhoff
  • Christian Münz

Abstract

The human tumor viruses Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) establish persistent infections in B cells. KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also contain EBV. Studies on persistent KSHV infection in vivo and the role of EBV co-infection in PEL development have been hampered by the absence of small animal models. We developed mice reconstituted with human immune system components as a model for KSHV infection and find that EBV/KSHV dual infection enhanced KSHV persistence and tumorigenesis. Dual-infected cells displayed a plasma cell-like gene expression pattern similar to PELs. KSHV persisted in EBV-transformed B cells and was associated with lytic EBV gene expression, resulting in increased tumor formation. Evidence of elevated lytic EBV replication was also found in EBV/KSHV dually infected lymphoproliferative disorders in humans. Our data suggest that KSHV augments EBV-associated tumorigenesis via stimulation of lytic EBV replication.

Bibliografische Daten

OriginalspracheEnglisch
ISSN1931-3128
DOIs
StatusVeröffentlicht - 12.07.2017
Extern publiziertJa
PubMed 28704654